Capability
Supporting executive leadership
Leadership decisions—buy, partner, pivot, or double down—need more than slides. We deliver integrated views of science, clinical risk, regulatory path, and commercial evidence so CEOs and boards can act with eyes open.
Boards and investors see hundreds of pipelines; they reward clarity on what could go wrong and what evidence would change the thesis. We translate complex development and access dynamics into decision-ready framing—without hiding uncertainty behind buzzwords or drowning executives in operational minutiae.
The leadership challenge
CEOs and boards must allocate capital across programs that differ in modality, evidence maturity, and competitive intensity—often with incomplete data and fixed decision windows. Clinical teams speak in endpoints; finance speaks in cash runway; business development speaks in deal multiples. Without integration, governance becomes a sequence of function-specific updates rather than a coherent risk picture. That gap shows up as surprise write-downs, delayed financings, and partnerships that looked attractive in a teaser but fray under diligence.
Executive support from lotor lab is designed to close that gap. We combine clinical and regulatory depth with access and evidence economics so leadership sees how science, time, and capital interact—not three parallel stories.
Where we focus
Diligence and transaction support
For licensing, M&A, and co-development, we triage data rooms efficiently: red-flag clinical design issues, regulatory pathway credibility, CMC readiness, and access headwinds. Deliverables include issue lists with severity, mitigations, and “what we need to see to upgrade our view”—so deal teams can negotiate from evidence, not hope.
Stage-gates and portfolio governance
We draft go / no-go memos that tie funding decisions to falsifiable milestones: trials that reduce specific uncertainties, agency interactions that validate pathway assumptions, and access evidence that supports price thesis. The emphasis is killing projects for the right reasons—and doubling down when the constellation of evidence justifies it.
Board and investor communications
We structure decks and Q&A prep around a single spine: mechanism, unmet need, proof points to date, development and regulatory path, access thesis, and capital plan. Uncertainty is classified—operational, scientific, regulatory, competitive—each with monitoring metrics.
Crisis and pivot moments
After failed readouts, clinical holds, or CRLs, leadership needs fast, honest reframing: what broke, what is still true, and what strategic options remain. We facilitate executive workshops that move from emotion to decision criteria within days, not weeks.
What we deliver
- Integrated diligence reports spanning clinical, regulatory, CMC, safety, and access—with executive summaries.
- Stage-gate and investment committee memos with explicit kill / continue logic.
- Board and investor decks, script notes, and anticipated Q&A with evidence citations.
- Scenario planning for label, pricing, and competitive outcomes tied to portfolio implications.
- Facilitation of leadership offsites, board scientific sessions, and partner summits.
- Post-mortems and learning reviews after major decisions to institutionalize judgment.
Outcomes you can expect
- Fewer “unknown unknowns” in diligence that surface only after sign-off.
- Clearer, faster decisions on pivots, pauses, and exits because trade-offs were pre-structured.
- Boards and investors who trust management’s evidence narrative because limitations were named upfront.
- Better alignment between R&D ambition and capital markets messaging.
How we work
Our portfolio-leadership background and clinical R&D experience mean we speak both science and capital. We do not bury uncertainty; we classify it—known unknowns addressable with studies versus structural risks to the thesis. That is the same adaptable, evidence-first mindset that defines lotor lab on operating programs, applied at C-suite altitude.
We operate as trusted advisors to CEOs, CSOs, and boards—supplementing internal strategy and transaction teams. We respect confidentiality, move at deal speed when required, and anchor every recommendation in traceable evidence.
When teams bring us in
- BD processes with compressed timelines, incomplete data rooms, or noisy vendor reports.
- Financing, IPO, or partnership milestones requiring a crisp, diligence-resistant story.
- Portfolio reviews and capital reallocation decisions across multiple modalities or indications.
- Strategic pivots after unexpected trial, regulatory, or competitive events.